Medical Doctor Program year 2022 Source: CMS Open Payments, 2026 publication

Jose Nin Torregrosa

Internal Medicine San Juan, PR Medical Doctor

NPI 1043294309 CMS profile 1288703

Ponce De Leon Ave Stop 25.5, Mercantil Plaza Suite 618, San Juan, PR 00918

Open in the dashboard

General payments

$100

1 record reported · program year 2022

Research payments

$0

Paid to them · None reported · program year 2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jose Nin Torregrosa of San Juan, PR is reported in the CMS Open Payments database as having received $100 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2022 General $100 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Nin Torregrosa
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jose Nin Torregrosa were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jose Nin Torregrosa Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $100 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program year 2022
  1. AstraZeneca Pharmaceuticals LP $100 1 payment

Every payment, record by record

What the payments were for General payments · program year 2022
  1. Education $100 1 payment
Products named General payments · program year 2022
  1. LOKELMA $100 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

560

Median for Internal Medicine: 777

Drug cost

$9,890

Median for Internal Medicine: $73,373

Branded share of claims

5.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Allopurinol Generic 312 $5,170
Synthroid Levothyroxine Sodium Brand 32 $1,841
Irbesartan Generic 13 $740
Losartan Potassium Generic 30 $436
Atorvastatin Calcium Generic 25 $384
Tamsulosin Hcl Generic 18 $321
Gabapentin Generic 24 $250
Hydrochlorothiazide Generic 40 $229
Metformin Hcl Generic 22 $185
Levothyroxine Sodium Generic 15 $156

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record